Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urologic Neoplasms 1Pain 1Operable Breast Cancer 1Neoplasms 1Malignant Pleural Neoplasm 1Liver Neoplasms 1Breast Neoplasms 1Agnosia 1

Interventions

durvalumab 7Bevacizumab 6tremelimumab 3Nivolumab 3lenvatinib 2fludarabine 2Cyclophosphamide 2zimberelimab 1toripalimab 1ropidoxuridine 1relatlimab 1pembrolizumab 1fludarabine phosphate 1atezolizumab 1X-Rays 1Technetium Tc 99m Aggregated Albumin 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Platinum 1Photons 1Paclitaxel 1Observation 1Long-Term Potentiation 1Lidocaine 1Immunotherapy 1Immunoglobulin G 1IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Liver Neoplasms × Lidocaine × Clear all
NCT07034950 2025-09-11

Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation

The First Affiliated Hospital of Xiamen University

Phase 1/2 Active not recruiting
79 enrolled
Gastrointestinal

Liver Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡